S07-1066

S07-1066 is an aldo-keto reductase 1C3 (AKR1C3) inhibitor, synergizing doxorubicin (DOX) cytotoxicity. S07-1066 selectively blocks AKR1C3-mediated reduction of DOX, and reverses the DOX resistance in overexpressing AKR1C3 cells[1].

Product Specifications

CAS Number

[876625-29-5]

UNSPSC

12352005

Target

17β-HSD

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/s07-1066.html

Concentration

10mM

Purity

99.48

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

ClC1=CC(Cl)=CC(C2=CC=C(C3(C(O)=O)CC3)C=C2F)=C1

Molecular Formula

C16H11Cl2FO2

Molecular Weight

325.16

References & Citations

[1]He S, et al. Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment. J Med Chem. 2023 Jul 6.